# Electra Therapeutics Inc. (ETRA)

Source: https://www.quantisnow.com/company/ETRA
Generated: 2026-11-18T02:06:01.027Z

- Ticker: ETRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2026
- SEC CIK: 0002088082
- Website: https://electra-therapeutics.com

## About

Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company's lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies.

## Latest ETRA news and filings

- 2026-11-16 19:00 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Electra Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-electra-therapeutics-inc-6793691)
- 2026-11-12 21:18 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Electra Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-electra-therapeutics-inc-6788205)
- 2026-11-12 21:17 UTC [SEC Form 8-K] [Electra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/electra-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6788165)
- 2026-11-12 21:01 UTC [Earnings] [Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights](https://www.quantisnow.com/insight/electra-therapeutics-reports-third-quarter-2026-financial-results-and-recent-6787483)
- 2026-11-11 01:14 UTC [Insider Buy] [Director Gordon Carl L bought $744,531 worth of shares (92,116 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/director-gordon-carl-l-bought-744531-worth-of-shares-92116-6784983)
- 2026-11-11 01:09 UTC [Insider Buy] [Director Orbimed Advisors Llc bought $744,531 worth of shares (92,116 units at $8.08) (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-bought-744531-worth-of-shares-92116-6784980)
- 2026-11-05 22:47 UTC [Insider Buy] [Director Gordon Carl L bought $3,605,116 worth of shares (472,571 units at $7.63) (SEC Form 4)](https://www.quantisnow.com/insight/director-gordon-carl-l-bought-3605116-worth-of-shares-472571-6777516)
- 2026-11-05 22:39 UTC [Insider Buy] [Director Orbimed Advisors Llc bought $3,605,116 worth of shares (472,571 units at $7.63) (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-bought-3605116-worth-of-shares-472571-6777495)
- 2026-11-04 13:00 UTC [Conference Announcement] [Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/electra-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-6771428)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ETRA
- Earnings history: https://www.quantisnow.com/earnings/ETRA
- Dividend history: https://www.quantisnow.com/dividends/ETRA
- Insider transactions: https://www.quantisnow.com/insiders/ETRA
- Options chain: https://www.quantisnow.com/options/ETRA
- SEC 8-K filings only: https://www.quantisnow.com/company/ETRA/8-k
- RSS and alerts for ETRA: https://www.quantisnow.com/docs/rss-feeds.md
